CJC-1295 (DAC) — 2mg

CJC-1295 (with DAC — Drug Affinity Complex) is a synthetic analog of growth hormone-releasing hormone (GHRH) modified with special DAC technology for a strongly extended half-life. Each vial contains 2mg of lyophilized CJC-1295 DAC, ≥99% purity, HPLC tested. CJC-1295 stimulates the pituitary to produce and release its own growth hormone (GH) in a physiological manner. The DAC modification extends the half-life from about 30 minutes to 8–10 days. As a result, weekly dosing is enough for continuous GH elevation. In research protocols CJC-1295 is virtually always combined with a GHRP such as Ipamorelin for synergistic GH secretion. The CJC-1295 + Ipamorelin combination is regarded as the most popular peptide combination in scientific research for growth hormone optimization. In studies, doses of 1–2mg per week are administered subcutaneously. The substance requires reconstitution with bacteriostatic water. For laboratory and research purposes only.

Post Cycle Therapy (PCT) is not required after CJC-1295 use. The peptide stimulates the pituitary's own GH production and does not suppress testosterone production.